Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisP

UK bans, Health Canada warns about antidepressants

Wayne Kondro
CMAJ July 06, 2004 171 (1) 23; DOI: https://doi.org/10.1503/cmaj.1040981
Wayne Kondro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Six months after the UK banned antidepressant drugs for children, Health Canada has issued a warning that using 7 of the medications may make patients worse.

Figure

Figure. Photo by: Comstock

Patients of all ages taking fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), mirtazapine (Remeron), fluoxetine (Prozac) and citalopram (Celexa), as well as those taking bupropion as an antidepressant (Wellbutrin) or smoking cessation drug (Zyban) may “experience behavioural and/or emotional changes that may put them at increased risk of self-harm or harm to others,” Health Canada cautioned June 4 in a directive to physicians and consumers.

Recent studies have indicated that selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenalin reuptake inhibitors (SNRIs) may worsen depression or trigger suicidal or aggressive impulses.

In December 2003, the UK banned the use of 4 antidepressants for children; it had banned 2 others earlier last year. The US Food and Drug Administration followed on March 22 with a strongly worded warning about the drugs.

But the chair of a 5-member expert advisory panel Health Canada convened to assess SSRIs does not believe the evidence supports a British-style ban or a stronger warning, he says. The more “measured” Canadian response puts the issue in proper perspective for physicians, says Dr. Yvon Lapierre. “There is some evidence that maybe this is happening, sufficient to give you this warning, but not to remove it from the market.”

Manufacturers will be required to amend their product monographs, patients will be notified through an information sheet accompanying their prescriptions, and physicians will receive letters informing them of the risk, says Health Canada spokesperson Jirina Vlk.

Patients who experience suicidal impulses or feelings of agitation, hostility or anxiety are urged to consult their doctor rather than discontinuing the medication abruptly, which may provoke serious withdrawal symptoms.

“The Americans have taken the same attitude as we have in Canada: be careful,” says Lapierre. “Treat your patients properly. Keep an eye on them and you shouldn't have any problems.”

An article by Lapierre (J Psychiatry Neurosci 2003;28[5]:340-7) concluded there is little evidence that SSRIs cause increased suicidality.

The delay in Health Canada's response to concerns about the drugs was necessary, says Vlk, because reviewers examined more than 70 brand-name and generic versions of the medications licensed in Canada. — Wayne Kondro, Ottawa

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (1)
CMAJ
Vol. 171, Issue 1
6 Jul 2004
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (93-100)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
UK bans, Health Canada warns about antidepressants
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
UK bans, Health Canada warns about antidepressants
Wayne Kondro
CMAJ Jul 2004, 171 (1) 23; DOI: 10.1503/cmaj.1040981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
UK bans, Health Canada warns about antidepressants
Wayne Kondro
CMAJ Jul 2004, 171 (1) 23; DOI: 10.1503/cmaj.1040981
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • Legal action against GSK over SSRI data
  • PubMed
  • Google Scholar

Cited By...

  • Health advisories: when good intentions go bad
  • Google Scholar

More in this TOC Section

  • The changing ecology of avian flu
  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire